O'Keefe Kenneth W's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Mar 9, 2023
- Accession no.
- 0001765581-23-000034
- Filed
- Mar 9, 2023
- Trade date
- Mar 7, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $372.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| O'Keefe Kenneth WCIK 0001397661 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2023 | Ordinary Shares | MOption exerciseAcquired | +4,500 | $81.76 | +$367,920 | 25,579 | Direct | |
| Mar 7, 2023 | Ordinary Shares | SSaleDisposed | −2,690 | $138.39 | −$372,269.1 | 22,889 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2023 | Ordinary Shares | MOption exerciseDisposed | −4,500 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.